A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001

NCT ID: NCT01559818

Last Updated: 2023-06-22

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-02-29
• Study Completion Date: 2019-07-31

Brief Summary

Patients who were previously enrolled in Study IMM-101-001 and who provided informed consent were eligible to participate in this study.

Once eligibility was confirmed, a full medical history covering the period from completion of Study IMM-101-001 to date was taken.

The treatment regimen with IMM-101 was one dose given every 4 weeks or as close to this interval as permitted due to practical or logistic considerations. The dose interval could be modified at the discretion of the Investigator provided the minimum period between doses was no less than 14 days.

The overall objective was to determine the long term safety profile of IMM-101 administered intradermally for extended use.

Detailed Description

This was an open-label long term follow up study. The study consisted of two phases:

1. Screening and enrolment Patients, who provided informed consent participated in a screening period of up to 28 days to establish eligibility. Once eligibility was confirmed a full disease and treatment history covering the period from their completion of Study IMM-101-001 to date was taken.

2. Treatment Patients could receive ongoing treatment every 4 weeks or as close to this interval as permitted due to practical or logistic considerations until death or withdrawal, unless such therapy was contraindicated, the patient did not wish to continue or the study was terminated by the Sponsor. At no point could the elapsed period between IMM-101 doses be less than 14 days.

Patients could choose to withdraw from the study at any time and for any reason. IMM-101 could be stopped or the dosing regimen reduced if felt to be necessary by the Investigator and/or patient (e.g., intolerable injection site reactions).

In the event of an injection site reaction of Grade 3 and above, and/or if significant ulceration, tenderness or lymphadenopathy was observed, at the discretion of the Investigator, patients could be administered a half dose of the study drug (i.e., a single 0.05 mL intradermal injection of IMM-101) or the timing of the injection could be delayed. If the dosing interval was increased, the patient still attended the study site for safety assessments preferably every 3 months but, if this was not possible, every 6 months at a minimum. The blood sample for exploratory analysis continued to be taken every 6 months.

Any change in the dose of study drug administered or the frequency of dose administration was recorded in the patient's case report form (CRF). In the case of withdrawal, separate consent was sought to allow the continued collection on patient status.

Conditions

Malignant Melanoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

IMM-101

IMM-101 1.0 mg administered intradermally

Group Type: EXPERIMENTAL

IMM-101

Intervention Type: BIOLOGICAL

IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline.

Interventions

IMM-101

IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline.

Intervention Type: BIOLOGICAL

Other Intervention Names

Heat-killed whole cell M. obuense

Eligibility Criteria

Inclusion Criteria

• Patient was previously enrolled in Study IMM-101-001
• Patient gave consent to make their disease and treatment history for the intervening period between their completion of Study IMM-101-001 and enrollment in this study available to the Sponsor
• Patient gave signed informed consent for participation in the study

Exclusion Criteria

• Female patient of child-bearing potential who was not, in the opinion of the Investigator, using an approved method of birth control (e.g., physical barrier [patient and partner], contraceptive pill or patch, spermicide and barrier, or intrauterine device [IUD]).

Those patients that utilised hormonal contraceptives must have used the same method for at least three months before additional barrier contraception (as described above) was discontinued from being used concomitantly with the hormonal contraception.

• Patient of non-child-bearing potential were defined as having 12 month amenorrhoea or were surgically sterile.
• Female patient who was pregnant, breast feeding or planning a pregnancy during the course of the study. A pre-treatment urine pregnancy test measuring human chorionic gonadotrophin (hCG) must be negative.
• Patient was unable or unwilling to comply with the protocol.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Immodulon Therapeutics Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alberto Fusi, Dr

Role: PRINCIPAL_INVESTIGATOR

St George's, University of London

Locations

St Georges University of London

London, , United Kingdom

Countries

United Kingdom

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

IMM-101-008

Identifier Type: -

Identifier Source: org_study_id